摘要
目的观察噻托溴铵与沐舒坦联合应用对AECOPD患者肺功能的保护作用。方法共收集2015年1月~2016年10月期间我院收治的110例AECOPD患者作为研究对象,将110例患者按照治疗方法分为两组,研究组和对照组,每组各55例。两组患者给予常规治疗,包括吸氧、抗炎、补液、纠正电解质紊乱及维持酸碱平衡、给予止咳平喘药物及对症治疗,除此之外,研究组用噻托溴铵与沐舒坦联合治疗,比较两组临床疗效及治疗前后第1秒用力呼气容积(FEV1)、FEV1/1秒用力肺活量(FVC)。结果研究组总有效率为92.73%,对照组总有效率为76.36%,研究组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,研究组和对照组FEV1、FEV1/FVC相较于治疗前明显升高,与治疗前比较差异有统计学意义(P<0.05);治疗后研究组FEV1、FEV1/FVC高于对照组,两组差异有统计学意义(P<0.05)。结论噻托溴铵与沐舒坦联合应用于AECOPD治疗中效果显著,可提高临床治疗总有效率,改善患者的肺功能,建议在临床推广应用。
Objective To observe the protective effect of Levetiracetam combined with Mucosolvan on pulmonary func- tion in patients with AECOPD. Methods A total of 110 patients with AECOPD admitted in our hospital from January 2015 to October 2016 were enrolled in this study. The 110 patients were divided into two groups according to the treatment methods, including the study group（n=55） and the control group（n=55）. The two groups of patients were treated with conventional treatment, including oxygen, anti-inflammatory, fluid infusion, correcting electrolyte imbalance, maintaining acid-base balance, cough and asthma drugs and symptomatic treatment. In addition, the study group was given Levetiracetam combined with Mucosolvan treatment. The clinical efficacy, the first second forced expiratory volume （FEV1） and FEV1/1 second forced vital capacity（FVC） of the two groups before and after treatment were compared. Results The total effective rate was 92.73% in the study group and 76.36% in the control group. The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant（P〈0.05）. After treatment, FEV1 and FEV1/FVC in the study group and control group were significantly higher than those before treatment, with significant difference（P〈0.05）. After treatment, FEV1 and FEV1/FVC in the study group were higher than those in the control group. The differences between the two groups were statistically significant（P〈0.05）. Conclusion Levetiracetam combined with Mucosolvan used in the treatment of AECOPD has significant effect, which can improve the total effective rate of clinical treatment and improve the lung function of patients, and is recommended in the clinical application.
作者
聂洪洲
NIE Hongzhou(Department of Respiratory Medicine, Huludao City Lianshan District Hospi,tal in Liaoning Province, Huludao 125001, China)
出处
《中国现代医生》
2017年第24期118-120,共3页
China Modern Doctor
关键词
慢性阻塞性肺疾病
噻托溴铵
沐舒坦
肺功能
Chronic obstructive pulmonary disease
Levetiracetam
Mucosolvan
Pulmonary function
